32 related articles for article (PubMed ID: 10215697)
1. Human Enteroid Monolayers: A Novel, Functionally-Stable Model for Investigating Oral Drug Disposition.
Arian C; Mahony EO; MacDonald JW; Bammler TK; Donowitz M; Kelly EJ; Thummel KE
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38744527
[TBL] [Abstract][Full Text] [Related]
2. Perfluoropolyether-Based Gut-Liver-on-a-Chip for the Evaluation of First-Pass Metabolism and Oral Bioavailability of Drugs.
Wang M; Sasaki Y; Sakagami R; Minamikawa T; Tsuda M; Ueno R; Deguchi S; Negoro R; So K; Higuchi Y; Yokokawa R; Takayama K; Yamashita F
ACS Biomater Sci Eng; 2024 Jun; ():. PubMed ID: 38822812
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D3 Is Transformed into 1,25(OH)2D3 by Triggering CYP3A11(CYP3A4) Activity and Hydrolyzing Midazolam.
Zhu H; Wu R; Gu Z; Ji M; Xu Q
Med Sci Monit; 2019 Dec; 25():9159-9166. PubMed ID: 31787743
[TBL] [Abstract][Full Text] [Related]
4. Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism.
Yamaura Y; Chapron BD; Wang Z; Himmelfarb J; Thummel KE
Drug Metab Dispos; 2016 Mar; 44(3):329-35. PubMed ID: 26700954
[TBL] [Abstract][Full Text] [Related]
5. The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.
Chen EP; Tai G; Ellens H
Pharm Res; 2014 Feb; 31(2):305-21. PubMed ID: 23990312
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.
Korjamo T; Mönkkönen J; Uusitalo J; Turpeinen M; Pelkonen O; Honkakoski P
Pharm Res; 2006 Sep; 23(9):1991-2001. PubMed ID: 16951996
[TBL] [Abstract][Full Text] [Related]
7. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
Tolle-Sander S; Rautio J; Wring S; Polli JW; Polli JE
Pharm Res; 2003 May; 20(5):757-64. PubMed ID: 12751631
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
Horie K; Tang F; Borchardt RT
Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate.
Cummins CL; Mangravite LM; Benet LZ
Pharm Res; 2001 Aug; 18(8):1102-9. PubMed ID: 11587480
[TBL] [Abstract][Full Text] [Related]
10. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.
Gibbs MA; Baillie MT; Shen DD; Kunze KL; Thummel KE
Pharm Res; 2000 Mar; 17(3):299-305. PubMed ID: 10801218
[TBL] [Abstract][Full Text] [Related]
11. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
12. New insights into drug absorption: studies with sirolimus.
Paine MF; Leung LY; Watkins PB
Ther Drug Monit; 2004 Oct; 26(5):463-7. PubMed ID: 15385826
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro.
Deb S; Chin MY; Adomat H; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():50-8. PubMed ID: 24269662
[TBL] [Abstract][Full Text] [Related]
14. First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.
Fisher JM; Wrighton SA; Watkins PB; Schmiedlin-Ren P; Calamia JC; Shen DD; Kunze KL; Thummel KE
J Pharmacol Exp Ther; 1999 May; 289(2):1134-42. PubMed ID: 10215697
[TBL] [Abstract][Full Text] [Related]
15. Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding.
Fisher JM; Wrighton SA; Calamia JC; Shen DD; Kunze KL; Thummel KE
J Pharmacol Exp Ther; 1999 May; 289(2):1143-50. PubMed ID: 10215698
[TBL] [Abstract][Full Text] [Related]
16. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
Mouly SJ; Paine MF; Watkins PB
J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
